Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (793)	12/23/1998 6:52:00 PM
From: Craig A	Respond to of 1686

Just heard Joe Kernan on CNBC discuss the situation. The company reasures that no fundamentals have changed. New CEO on Squalkbox tomorrow. Anaylist just before him playing up BGEN. IID newsletter I subscribe to has BGEN #1 Buy . They use a consensus of newsletters. I am selling something tommorow and buyin more BGEN. MS drug New to this group Happy Happy to all. Peace Craig

To: Harold Engstrom who wrote (793)	12/23/1998 6:54:00 PM
From: PuddleGlum	Read Replies (4) \| Respond to of 1686

Harold- An 8% drop on more than 10x average volume is not encouraging. Why did the stock drop all the way to $70 just on news of a mgmt change? This may have been an excuse for someone in-the-know to get out. That said, I bought back the shares today that I had previously sold at $80. Volume of 1M shares in the last several minutes of trading pushed the stock up $1. The bad news from a point and figure standpoint is that the stock violated its bullish support line and failed an extremely positive bullish catapult formation and it has plenty of resistance at 81-82. pg

To: Harold Engstrom who wrote (793)	12/24/1998 11:41:00 AM
From: Vector1	Read Replies (3) \| Respond to of 1686

Harold, This whole Vincent /Tobin situation is bizare. Fundamentally the company has not changed. Right now I would sit tight or be a buyer. Here are my reasons: I don't sell a stock I have a large gain in unless I think it is over valued by more than 10%. I take taxes on into consideration. I think BGEN is fairly valued at $75-90. I think the company will blow away analyst estimates in for the fourth quarter. They clearly have been saving for a rainy day by undereporting revenue. Good companies do this. VIncent will want the first couple of quarters where he is back at the helm to be very strong and they have the ability to do that. I intend to hold until the stock hits $90 which I believe that it will do in by mid Jan. Then I will sell covered calls at $95to 100 with a mid year expiration. With the volitility in the stock it allows me to lock in a nice addtional return without having to sell the stock and pay taxes during the annual summer biotech slump. I don't think we will see data on anti CD 40 until the Fourth Quarter. Happy Holidays. V1